A Surbiton couple is backing a UK-wide campaign to raise awareness of a rare form of epilepsy that affects their daughter. Jennifer and Tom Allen's nine-year-old daughter, Beth, has Dravet Syndrome.

The company has already secured approval for Fintepla in treating Dravet syndrome and Lennox-Gastaut syndrome.

A little baby suffering a seizure is an incredibly distressing event for a family. Epilepsy is the most common neurological disorder in children and it takes the form of recurring seizures. But ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Alternative therapies, like medical cannabis, may help people manage their seizures better. They can be included alongside your normal treatment plan.

A Surbiton couple, whose 9 year-old daughter has Dravet Syndrome, a rare, life-limiting, form of epilepsy, are backing a ...

Dravet Syndrome occurs in around one in every 15,000 live births and is among the most treatment-resistant genetic epilepsies.

UCB’s continued commitment to leading research aimed at improving treatment outcomes for people living with neurological conditions.Data include the use of FINTEPLA®▼ (fenfluramine)1 in Dravet ...

The Stanley Brothers created Charlotte's Web, the CBD supplement that’s worked wonders on seizures. Now they are developing ...

UCB has shared promising results from a late-stage study of fenfluramine in patients with an ultra-rare form of epilepsy. The ...

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...